Catalyst
Slingshot members are tracking this event:
Phase II simtuzumab HVPG cirrhosis data in portal hypertension expected near year end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 20, 2016
Occurred Source:
http://www.gilead.com/news/press-releases/2016/10/gilead-announces-topline-phase-2-results-for-gs4997-selonsertib-in-nonalcoholic-steatohepatitis-nash-pulmonary-arterial-hypertension-pah-and-diabetic-kidney-disease-dkd
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Simtuzumab, Hvpg Cirrhosis, Portal Hypertension
